

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-18 (cancelled).

Claim 19 (Currently Amended): A method of reducing the risk of developing multiple organ dysfunction in a mammal suffering from a trauma or that will suffer from said trauma, the trauma being selected from the group consisting of surgery, burns, lesions and hemorrhage, comprising identifying the said mammal that suffers from said trauma or that will suffer from said trauma, and enterally administering to said mammal an aqueous liquid composition comprising (i) a liver guanosine-5'-triphosphate (GTP) increasing component and (ii) a digestible water soluble carbohydrate within 24 hours of the occurrence of the trauma, wherein the liver GTP increasing component being selected from the group consisting of: 2-2000 mg guanosine, 0.5-40 g ribose and combinations thereof, wherein the guanosine is selected from the group consisting of guanosine, guanosine salt, guanosine-5' triphosphate, guanosine ester and combinations thereof, and wherein the ribose is selected from the group consisting of ribose, ribonucleoside, ribose ester and combinations thereof; and the digestible water soluble carbohydrates being in an amount of at least 20 g and in the form of the aqueous liquid composition containing at least 10 g/l of said digestible water soluble carbohydrates.

Claim 20 (Withdrawn): The method according to claim 19, further comprising administering, within 24 hours of the occurrence of the trauma, 0.05-100 mmole of peptides with Angiotensin Converting Enzyme (ACE) inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M.

Claim 21 (Withdrawn): A method of preventing multiple organ dysfunction in a mammal suffering from trauma, comprising enterally administering an aqueous liquid composition comprising digestible water soluble carbohydrates; and (i) 0.05-100 mmole of peptides with ACE inhibiting activity within 24 hours of the occurrence of the trauma, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M; and (ii) at least 20 g of the digestible water soluble carbohydrates in the form of the aqueous liquid composition containing at least 10 g/l of said digestible water soluble carbohydrates.

Claim 22 (Withdrawn): The method according to claim 21, further comprising administering, within 24 hours of the occurrence of the trauma, a liver GTP increasing component selected from the group consisting of: 2-2000 mg guanosine equivalents; 0.1-10 g folic acid equivalents; 0.5-40 g ribose equivalents; and combinations thereof.

Claim 23 (Previously Presented): The method according to claim 19, wherein the trauma is surgery.

Claim 24 (Previously Presented): The method according to claim 23, wherein the surgery is prescheduled surgery.

Claim 25 (Previously Presented): The method according to claim 23, wherein the liquid composition is administered within 24 hours prior to the occurrence of the surgery.

Claim 26 (Withdrawn): The method according to claim 19, wherein the liquid composition contains between 30 and 200 g/l of digestible polysaccharides.

Application No. 10/572,239  
Paper Dated: December 29, 2010  
In Reply to USPTO Correspondence of July 30, 2010  
Attorney Docket No. 0470-060781

Claim 27 (Withdrawn): The method according to claim 19, wherein the digestible water soluble carbohydrates are selected from the group consisting of dextrins, maltodextrins, starches, dextran and combinations thereof.

Claim 28 (Previously Presented): The method according to claim 19, wherein at least 50 g of the digestible water soluble carbohydrates is enterally administered in the form of the aqueous liquid composition.

Claim 29 (Previously Presented): The method according to claim 19, wherein 2-2000 mg guanosine is enterally administered within 24 hours of the occurrence of the trauma.

Claim 30 (Withdrawn): An aqueous liquid composition suitable for enteral administration, comprising:

20-200 g/l digestible dissolved carbohydrates;  
5-5000 mg/l guanosine equivalents;  
at least one of 1-100 g/l ribose equivalents and 2-2000 mg/l flavonoides; and  
45 to 97.95 wt.% water.

Claim 31 (Withdrawn): The aqueous liquid composition according to claim 30, wherein the aqueous liquid composition is comprised of 5-5000 mg/l guanosine equivalents and at least 1-100 g/l ribose equivalents.

Claim 32 (Withdrawn): An aqueous liquid composition suitable for enteral administration, comprising:

20-200 g/l digestible dissolved carbohydrates;  
0.01 to 10 mM of peptides with ACE inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M;

at least one of:

5-5000 mg/l guanosine equivalents;  
1-100 g/l ribose equivalents;  
0.2 and 400 mg/l folic acid equivalents;  
2-2000 mg/l flavonoides; and  
45 to 97.95 wt.% water.

Claim 33 (Withdrawn): The aqueous liquid composition according to claim 32, wherein the composition contains 5-5000 mg/l guanosine equivalents and/or 1-100 g/l ribose equivalents.

Claim 34 (Withdrawn): The aqueous liquid composition according to claim 30, further comprising between 0.2 and 400 mg/l folic acid equivalents.

Claim 35 (Withdrawn): The aqueous liquid composition according to claim 30 suitable for enteral administration, further comprising 0.01 to 10 mM of peptides with ACE inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M, wherein the liquid composition is a clear aqueous solution.

Claim 36 (Withdrawn): A composition that can be reconstituted with water to a liquid composition according to claim 30.

Claim 37 (Withdrawn): The method according to claim 19, wherein the liquid composition further comprises 0.1 to 10 mg of folic acid.

Claim 38 (Withdrawn): The method according to claim 19, wherein the liquid composition further comprises 0.1 to 50 mmoles of a peptide having ACE-inhibiting activity.

Application No. 10/572,239  
Paper Dated: December 29, 2010  
In Reply to USPTO Correspondence of July 30, 2010  
Attorney Docket No. 0470-060781

Claim 39 (Withdrawn): The method according to claim 19, wherein the liquid composition further comprises 1 to 100 mg of a flavonoid.